Form 4: MAIA Biotechnology CEO Vlad Vitoc Reports Stock Option Grant

Vlad Vitoc, CEO of MAIA Biotechnology, reports the acquisition of 400,000 stock options.

Summary

• On May 14, 2025, Vlad Vitoc, the CEO of MAIA Biotechnology, Inc., was granted 400,000 stock options.
• The options have an exercise price of $1.76.
• The options vest over a 4-year period, with 25% vesting on the first anniversary and the remaining options vesting monthly over the following 36 months.
• The options expire on May 14, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices. The grant of options aligns management's interests with shareholders.

Positives

• The grant of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.

Risks

• The vesting schedule could incentivize short-term decision-making to meet vesting milestones.

Future Outlook

This document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
• The vesting schedule of 4 years with a 1-year cliff is a typical structure for such grants.
• Comparable companies such as Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CEO to increase shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, MAIA Biotechnology, Vlad Vitoc, CEO, equity incentive plan, Form 4, beneficial ownership